The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
Subscribe to:
Post Comments (Atom)
-
Fellows of the European AI & Society Fund, here
-
CJEU, here . Judging from the press release, this is a victory on every front. And, this time, quite literally without appeal. Whether EU...
-
Ruling here.
-
CMA in the interregnum, here.
-
EV, EV
-
OECD, here. Tbd today, Trento U.
-
While Trump at the G7 Meeting just said in Macron's face "I'm the boss", cheerful atmosphere in sunny Brussels. After twen...
-
A. Agrawal, J. Gans, and A. Goldfarb, here .
No comments:
Post a Comment